REFERENCE
Speakman M, Khullar V, Mundy A, Odeyemi I, Bolodeoku J.A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. Current Medical Research and Opinion 24: 2173-2179, No. 8, Aug 2008
Rights and permissions
About this article
Cite this article
Solifenacin economically dominant in OAB. Pharmacoecon. Outcomes News 563, 1 (2008). https://doi.org/10.2165/00151234-200805630-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200805630-00001